Evidence map›Paper›PMID 25410655›Full record

ArticleGenes and immunity

Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs.

Steven R Presnell, Ahmad Al-Attar, Frank Cichocki, Jeffrey S Miller, Charles T Lutz

Open access · greenAbstract read
In one paragraph

Article in Genes and immunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Expert opinion on therapeutic targets · 2024
    Review
  2. Review
  3. Article
  4. MicroRNA-181 in cardiovascular disease: Emerging biomarkers and therapeutic targets.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  5. Article
  6. Associations ofInternational journal of molecular sciences · 2022
    Article
  7. Review
  8. Article
  9. Cancer immunology research · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Steven R Presnell *Departments of Pathology and Laboratory Medicine, University of Kentucky Lexington, Kentucky, USA.
Ahmad Al-Attar *Departments of Pathology and Laboratory Medicine, University of Kentucky Lexington, Kentucky, USA.
Frank CichockiDivision of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Jeffrey S MillerDivision of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Charles T LutzDepartments of Pathology and Laboratory Medicine, University of Kentucky Lexington, Kentucky, USA.
University of Kentucky · USMasonic Cancer CenterUniversity of Minnesota Medical Center · US

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA177558NIAID NIH HHS R01 AI56506PHS HHS R01 55417
6 · The paper itself

Abstract

Natural killer (NK) and T lymphocytes share many properties, yet only NK cells respond rapidly to infection and cancer without pre-activation. We found that few microRNAs (miRNAs) differed significantly between human NK and T cells. Among those miRNAs, miR-181a and miR-181b levels rose during NK cell differentiation. Prior studies indicate that miR-181a and miR-181b are critical for human NK cell development and are co-transcribed from genes on chromosome 1 (MIR181A1B1) and on chromosome 9 (MIR181A2B2). We mapped human MIR181A1B1 and MIR181A2B2 transcription start sites to 78.3 kb and 34.0 kb upstream of the mature miRNAs, generating predominantly unspliced transcripts of 80-127 kb and ~60 kb, respectively. Unlike mouse thymocytes, human T cells expressed both MIR181A1B1 and MIR181A2B2. We tested the hypothesis that NK cells differentially transcribe the two genes during development and in response to immune regulatory cytokines. During NK-cell differentiation, MIR181A2B2 expression rose markedly and exceeded that of MIR181A1B1. TGF-β treatment increased NK-cell MIR181A2B2 transcription, whereas IL-2, IL-15 and IL-12/IL-18 treatments upregulated MIR181A1B1. The MIR181A2B2 promoter was strongly transactivated by SMAD3 and SMAD4 transcription factors, suggesting that TGF-β signaling upregulates MIR181A2B2 expression, at least in part, through SMAD-dependent promoter activation.

Indexed as

Transcription Initiation SiteGene ExpressionHumansKiller Cells, NaturalMicroRNAsPromoter Regions, GeneticT-LymphocytesMicroRNAsMIrn181 microRNA, human

Identifiers

PMID25410655
PMCPMC4304976
OpenAlexW1980924310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.